BREZANI, Veronika, Nicolas BLONDEAU, Jan KOTOUCEK, Eva KLÁSKOVÁ, Karel ŠMEJKAL, Jan HOŠEK, Eliska MASKOVA, Pavel KULICH, Vilailak PRACHYAWARAKORN, Catherine HEURTEAUX and Josef MASEK. Enhancing Solubility and Bioefficacy of Stilbenes by Liposomal Encapsulation-The Case of Macasiamenene F. ACS Omega. WASHINGTON: American Chemical Society, 2024, vol. 9, No 8, p. 9027-9039. ISSN 2470-1343. Available from: https://dx.doi.org/10.1021/acsomega.3c07380.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Enhancing Solubility and Bioefficacy of Stilbenes by Liposomal Encapsulation-The Case of Macasiamenene F
Authors BREZANI, Veronika, Nicolas BLONDEAU, Jan KOTOUCEK, Eva KLÁSKOVÁ, Karel ŠMEJKAL, Jan HOŠEK, Eliska MASKOVA, Pavel KULICH, Vilailak PRACHYAWARAKORN, Catherine HEURTEAUX and Josef MASEK.
Edition ACS Omega, WASHINGTON, American Chemical Society, 2024, 2470-1343.
Other information
Original language English
Type of outcome Article in a journal
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.100 in 2022
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.1021/acsomega.3c07380
UT WoS 001164649600001
Tags 14110516
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 16/8/2024 08:12.
Abstract
Stilbenes in food and medicinal plants have been described as potent antiphlogistic and antioxidant compounds, and therefore, they present an interesting potential for the development of dietary supplements. Among them, macasiamenene F (MF) has recently been shown to be an effective anti-inflammatory and cytoprotective agent that dampens peripheral and CNS inflammation in vitro. Nevertheless, this promising molecule, like other stilbenes and a large percentage of drugs under development, faces poor water solubility, which results in trickier in vivo administration and low bioavailability. With the aim of improving MF solubility and developing a form optimized for in vivo administration, eight types of conventional liposomal nanocarriers and one type of PEGylated liposomes were formulated and characterized. In order to select the appropriate form of MF encapsulation, the safety of MF liposomal formulations was evaluated on THP-1 and THP-1-XBlue-MD2-CD14 monocytes, BV-2 microglia, and primary cortical neurons in culture. Furthermore, the cellular uptake of liposomes and the effect of encapsulation on MF anti-inflammatory effectiveness were evaluated on THP-1-XBlue-MD2-CD14 monocytes and BV-2 microglia. MF (5 mol %) encapsulated in PEGylated liposomes with an average size of 160 nm and polydispersity index of 0.122 was stable, safe, and the most promising form of MF encapsulation keeping its cytoprotective and anti-inflammatory properties.
Links
GA22-03187S, research and development projectName: Racionální design částicových polysacharidových systémů pro přívod léčiv s širokým spekterem biologické aktivity k terapii sliznic (Acronym: 22-03187S)
Investor: Czech Science Foundation
GA23-04655S, research and development projectName: Role prenylace a glykosylace v protizánětlivé aktivitě a metabolismu přírodních fenolových látek
Investor: Czech Science Foundation, Role of prenylation and glycosylation patterns in anti-inflammatory activity and metabolism of natural phenolic compounds
PrintDisplayed: 31/8/2024 19:20